Skip to content
sellWeak10b5-1 plan

Khurram Jamil sold $83k of GALT

Chief Medical Officer at GALECTIN THERAPEUTICS INC. 16,250 shares at an average of $5.13, traded Jul 14, 2026, filed Jul 16, 2026.

Warning score
9
Value
$83k
16,250 shares
Holdings after
0
-100% from before
From 52-week low
+157%
low $2.08, close $5.34
From 52-week high
-18%
high $6.51, as of Jul 14, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $83k at market
    +9
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GALTOct 9, 2026 · close 3.94
Since filing Jul 16, 2026: -6.9%SPY +3.9% · excess -10.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001133416-26-000063, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 14, 2026MOption exercise
Common Stock10b5-1
+16,250$3.04$49k16,250Jul 16, 2026
Jul 14, 2026SOpen-market sale
Common Stock10b5-1
-16,250$5.13$83k0Jul 16, 2026
Jul 14, 2026MOption exercise
Stock option (right to buy)derivative10b5-1
-16,250$0.00$048,750Jul 16, 2026

Related signals

Other insiders at GALECTIN THERAPEUTICS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
GALTsell 210b5-1
GALECTIN THERAPEUTICS INC
Khurram Jamil
Chief Medical Officer
$262k
52,037 shares
-2555%
19Weak
GALTsell 210b5-1
GALECTIN THERAPEUTICS INC
Harold H. Shlevin
director
$151k
30,000 shares
-211%
8Weak
GALTsell 210b5-1
GALECTIN THERAPEUTICS INC
Khurram Jamil
Chief Medical Officer
$24k
7,557 shares
-100%
0Weak
GALTsell10b5-1
GALECTIN THERAPEUTICS INC
Khurram Jamil
Chief Medical Officer
$1,761
568 shares
-100%
23Weak
GALTbuy
GALECTIN THERAPEUTICS INC
Kary Eldred
director
$810
300 shares
+0%
35Weak
GALTsell 310b5-1
GALECTIN THERAPEUTICS INC
Jack W Callicutt
Chief Financial Officer
$233k
60,000 shares
-89%
28Weak
GALTsell 310b5-1
GALECTIN THERAPEUTICS INC
Khurram Jamil
Chief Medical Officer
$232k
60,000 shares
-100%
19Weak
GALTsell 310b5-1
GALECTIN THERAPEUTICS INC
Joel Lewis
President and CEO
$321k
84,000 shares
-9%
21Weak
GALTsell 410b5-1
GALECTIN THERAPEUTICS INC
Khurram Jamil
Chief Medical Officer
$33k
8,125 shares
-100%
16Weak
GALTbuy 210b5-1
GALECTIN THERAPEUTICS INC
Kary Eldred
director
$2,611
700 shares
+1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Khurram Jamil sold $83k of GALT | InsiderTell